Home Featured Page 192

Featured

Latest

The Psychedelic News Feed: December 8 – 14, 2025

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy and What Comes Next

The Psychedelic News Feed: December 1 – 7, 2025

The Psychedelic News Feed: November 24 – 30, 2025

Psychedelic Research Bulletin: December 2021

Nova Mentis Provides Corporate Update – 2022 Planned Catalysts

Filament Health and Cybin Therapeutics Announce Licensing Agreement

Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs

Psychedelic Bulletin: MindMed Co-Founder Resigns from Board; Global Coalition to Reschedule...

Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary...

PharmaDrug Announces Resignation of Director

PT284 – Jonathan Sabbagh – Ketamine-Assisted Psychotherapy and Collaborative Care

Mydecine to Launch Special Access Support and Supply Program in Canada...

MYND Life Sciences Announces Collaborative Research Agreement with the University of...

1...191192193...304 Page 192 of 304

The Psychedelic News Feed: December 8 – 14, 2025

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

The Psychedelic News Feed: December 8 – 14, 2025

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy and What Comes Next

The Psychedelic News Feed: December 1 – 7, 2025

The Psychedelic News Feed: November 24 – 30, 2025

Psychedelic Research Bulletin: December 2021

Nova Mentis Provides Corporate Update – 2022 Planned Catalysts

Filament Health and Cybin Therapeutics Announce Licensing Agreement

Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs

Psychedelic Bulletin: MindMed Co-Founder Resigns from Board; Global Coalition to Reschedule...

Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary...

PharmaDrug Announces Resignation of Director

PT284 – Jonathan Sabbagh – Ketamine-Assisted Psychotherapy and Collaborative Care

Mydecine to Launch Special Access Support and Supply Program in Canada...

MYND Life Sciences Announces Collaborative Research Agreement with the University of...

EDITOR PICKS

The Psychedelic News Feed: December 8 – 14, 2025

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY